• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与犬多中心高级 B 细胞淋巴瘤首次缓解诱导期早期复发相关的基因表达谱。

Gene expression profiles associated with early relapse during first remission induction in canine multicentric high-grade B-cell lymphoma.

机构信息

Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

出版信息

J Vet Med Sci. 2024 Jan 10;86(1):18-27. doi: 10.1292/jvms.23-0269. Epub 2023 Nov 13.

DOI:10.1292/jvms.23-0269
PMID:37952972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10849849/
Abstract

Although chemotherapy using CHOP-based protocol induces remission in most cases of canine multicentric high-grade B-cell lymphoma (mhBCL), some cases develop early relapse during the first induction protocol. In this study, we examined the gene expression profiles of canine mhBCL before chemotherapy and investigated their associations with early relapse during the first whole CHOP-based protocol. Twenty-five cases of mhBCL treated with CHOP-based protocol as first induction chemotherapy were included in this study. Sixteen cases completed the first whole CHOP-based protocol without relapse (S-group), and nine developed relapse during the chemotherapy (R-group). RNA-seq was performed on samples from neoplastic lymph nodes. Differentially expressed genes (DEGs) were extracted by the comparison of gene expression profiles between S- and R-groups, and the differences in the expression levels of these genes were validated by RT-qPCR. Extracted 179 DEGs included the genes related to chemokine CC motif ligand, T-cell receptor signaling pathway, and PD-L1 expression and PD-1 checkpoint pathway. We focused on chemokine CC motif ligand, and CCL4 was confirmed to be significantly downregulated in the R-group (P=0.039). We also focused on the genes related to T-cell signaling pathway, and CD3E (P=0.039), ITK (P=0.023), and LAT (P=0.023) genes were confirmed to be significantly upregulated in the R-group. The current results suggest that both changes in tumor cells and the interactions between tumor cells and immune cells are associated with the efficacy of the chemotherapy for first remission induction.

摘要

虽然基于 CHOP 方案的化疗在大多数犬多中心高级 B 细胞淋巴瘤(mhBCL)病例中诱导缓解,但有些病例在第一个诱导方案中早期复发。在这项研究中,我们检查了化疗前犬 mhBCL 的基因表达谱,并研究了它们与第一个基于全 CHOP 方案期间早期复发的相关性。本研究纳入了 25 例接受基于 CHOP 方案作为一线诱导化疗的 mhBCL 病例。16 例完成了第一个全 CHOP 方案且无复发(S 组),9 例在化疗期间复发(R 组)。对肿瘤性淋巴结样本进行 RNA-seq。通过 S 组和 R 组之间基因表达谱的比较提取差异表达基因(DEGs),并通过 RT-qPCR 验证这些基因表达水平的差异。提取的 179 个 DEGs 包括与趋化因子 CC 基序配体、T 细胞受体信号通路和 PD-L1 表达及 PD-1 检查点通路相关的基因。我们重点关注趋化因子 CC 基序配体,发现 CCL4 在 R 组中显著下调(P=0.039)。我们还重点关注与 T 细胞信号通路相关的基因,发现 CD3E(P=0.039)、ITK(P=0.023)和 LAT(P=0.023)基因在 R 组中显著上调。目前的结果表明,肿瘤细胞的变化以及肿瘤细胞与免疫细胞之间的相互作用均与首次缓解诱导化疗的疗效相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e0/10849849/3813da566a4d/jvms-86-018-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e0/10849849/453c26fd9a0d/jvms-86-018-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e0/10849849/b58983709e21/jvms-86-018-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e0/10849849/3813da566a4d/jvms-86-018-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e0/10849849/453c26fd9a0d/jvms-86-018-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e0/10849849/b58983709e21/jvms-86-018-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e0/10849849/3813da566a4d/jvms-86-018-g003.jpg

相似文献

1
Gene expression profiles associated with early relapse during first remission induction in canine multicentric high-grade B-cell lymphoma.与犬多中心高级 B 细胞淋巴瘤首次缓解诱导期早期复发相关的基因表达谱。
J Vet Med Sci. 2024 Jan 10;86(1):18-27. doi: 10.1292/jvms.23-0269. Epub 2023 Nov 13.
2
MicroRNA profiling in canine multicentric lymphoma.犬多中心性淋巴瘤的 microRNA 图谱分析。
PLoS One. 2019 Dec 11;14(12):e0226357. doi: 10.1371/journal.pone.0226357. eCollection 2019.
3
Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.在接受化疗后达到完全缓解的淋巴瘤犬临床复发前外周血微小残留病增加。
J Vet Intern Med. 2011 Mar-Apr;25(2):292-6. doi: 10.1111/j.1939-1676.2010.0675.x. Epub 2011 Feb 11.
4
Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and Doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction.用实时聚合酶链反应测量肿瘤性淋巴样细胞数量评价长春新碱、环磷酰胺和阿霉素治疗犬淋巴瘤的细胞减灭疗效。
J Vet Intern Med. 2011 Mar-Apr;25(2):285-91. doi: 10.1111/j.1939-1676.2011.0686.x. Epub 2011 Feb 11.
5
Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.英国42例犬中心母细胞性弥漫性大B细胞多中心淋巴瘤的临床表现、诱导治疗和挽救治疗的预后意义
Vet Comp Oncol. 2018 Jun;16(2):276-287. doi: 10.1111/vco.12378. Epub 2017 Dec 22.
6
RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy.25 例接受 CHOP 化疗的犬淋巴瘤基因表达的 RNA-Seq 分析。
BMC Res Notes. 2022 Mar 22;15(1):111. doi: 10.1186/s13104-022-06003-5.
7
Response-based modification of CHOP chemotherapy for canine B-cell lymphoma.基于反应的 CHOP 化疗方案改良用于治疗犬 B 细胞淋巴瘤。
Vet Comp Oncol. 2021 Sep;19(3):541-550. doi: 10.1111/vco.12693. Epub 2021 Mar 26.
8
Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?犬多中心淋巴瘤复发与CHOP方案各成分的时间关联评估:环磷酰胺是最薄弱环节吗?
Vet J. 2016 Jul;213:87-9. doi: 10.1016/j.tvjl.2016.04.013. Epub 2016 Apr 29.
9
Comprehensive analysis of gene expression profiles reveals novel candidates of chemotherapy resistant factors in canine lymphoma.基因表达谱的综合分析揭示了犬淋巴瘤化疗耐药因子的新候选者。
Vet J. 2017 Oct;228:18-21. doi: 10.1016/j.tvjl.2017.10.002. Epub 2017 Oct 8.
10
Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).对采用环磷酰胺、阿霉素、长春新碱和强的松化疗方案进行再治疗的淋巴瘤犬第二次缓解相关因素的评估:95例病例(2000 - 2007年)
J Am Vet Med Assoc. 2011 Feb 15;238(4):501-6. doi: 10.2460/javma.238.4.501.

引用本文的文献

1
Review of Molecular Technologies for Investigating Canine Cancer.用于研究犬类癌症的分子技术综述
Animals (Basel). 2024 Feb 29;14(5):769. doi: 10.3390/ani14050769.

本文引用的文献

1
The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis.弥漫大B细胞淋巴瘤肿瘤免疫微环境中免疫检查点的表达:临床病理特征与预后
Front Oncol. 2022 Dec 6;12:1069378. doi: 10.3389/fonc.2022.1069378. eCollection 2022.
2
A single-cell atlas of diffuse large B cell lymphoma.弥漫性大 B 细胞淋巴瘤的单细胞图谱。
Cell Rep. 2022 Apr 19;39(3):110713. doi: 10.1016/j.celrep.2022.110713.
3
STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma.
信号转导和转录激活因子3通过增强弥漫性大B细胞淋巴瘤中CCL4的转录活性促进细胞增殖。
Acta Haematol. 2022;145(4):371-383. doi: 10.1159/000521445. Epub 2021 Dec 14.
4
Identification of CCL4 as an Immune-Related Prognostic Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.鉴定CCL4作为与透明细胞肾细胞癌肿瘤增殖和肿瘤微环境相关的免疫相关预后生物标志物。
Front Oncol. 2021 Nov 24;11:694664. doi: 10.3389/fonc.2021.694664. eCollection 2021.
5
Construction and validation of a scoring system to predict resistance to chemotherapeutic drugs using gene expression profiles in canine lymphoma.构建并验证一个基于基因表达谱预测犬淋巴瘤化疗药物耐药性的评分系统。
Res Vet Sci. 2021 Jul;137:208-216. doi: 10.1016/j.rvsc.2021.05.007. Epub 2021 May 15.
6
Genome-wide DNA methylation and RNA-seq analyses identify genes and pathways associated with doxorubicin resistance in a canine diffuse large B-cell lymphoma cell line.全基因组 DNA 甲基化和 RNA-seq 分析鉴定与犬弥漫性大 B 细胞淋巴瘤细胞系中多柔比星耐药相关的基因和通路。
PLoS One. 2021 May 7;16(5):e0250013. doi: 10.1371/journal.pone.0250013. eCollection 2021.
7
is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma.是弥漫性大B细胞淋巴瘤的一种新型预后标志物。
Pharmgenomics Pers Med. 2021 Apr 1;14:397-408. doi: 10.2147/PGPM.S301718. eCollection 2021.
8
CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.CXCL12和CD3E作为膀胱癌肿瘤微环境调节指标及其与免疫浸润和分子亚型的相关性
Front Oncol. 2021 Mar 4;11:636870. doi: 10.3389/fonc.2021.636870. eCollection 2021.
9
Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.IL-2 诱导的酪氨酸激酶 ITK 及其抑制剂在疾病发病机制中的作用。
J Mol Med (Berl). 2020 Oct;98(10):1385-1395. doi: 10.1007/s00109-020-01958-z. Epub 2020 Aug 18.
10
Mechanisms of Multidrug Resistance in Cancer Chemotherapy.癌症化疗中的多药耐药机制。
Int J Mol Sci. 2020 May 2;21(9):3233. doi: 10.3390/ijms21093233.